AGIX KraneShares Artificial Intelligence ETF

ATLANTA, March 2 /PRNewswire-FirstCall/ -- AtheroGenics, Inc. (NASDAQ:AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, announced today that Russell M. Medford, M.D., President and Chief Executive Officer, is scheduled to present at two investor conferences in March 2006. (Logo: http://www.newscom.com/cgi-bin/prnh/20040730/ATATHEROGENICSLOGO ) Dr. Medford will present a company overview and update at: - Cowen & Co.'s 26th Annual Health Care Conference on Tuesday, March 7, 2006, at 10:30 a.m. EST at the Boston Marriott Copley Place in Boston, Massachusetts; and - Lehman Brothers' Ninth Annual Global Healthcare Conference on Thursday, March 9, 2006, at 11:15 a.m. EST at Loews Miami Beach Hotel in Miami, Florida. A live audio webcast of the presentations will be available via a link on the Company's Investor Relations website at http://www.atherogenics.com/, under the "Investor Calendar" tab. A replay of the presentations will be available for 14 days. About AtheroGenics AtheroGenics is focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, including heart disease (atherosclerosis), rheumatoid arthritis and asthma. The Company has two drug development programs currently in the clinic. AtheroGenics' lead compound, AGI-1067, is being evaluated in the pivotal Phase III ARISE clinical trial as an oral therapy for the treatment of atherosclerosis in collaboration with AstraZeneca. AGI-1096 is a novel, oral agent in Phase I that is being developed for the prevention of organ transplant rejection in collaboration with Astellas. AtheroGenics also has preclinical programs in rheumatoid arthritis and asthma utilizing its proprietary vascular protectant(R) technology. For more information about AtheroGenics, please visit http://www.atherogenics.com/. http://www.newscom.com/cgi-bin/prnh/20040730/ATATHEROGENICSLOGO http://photoarchive.ap.org/ DATASOURCE: AtheroGenics, Inc. CONTACT: Donna L. Glasky, Corporate Communications of AtheroGenics, Inc., +1-678-336-2517, or ; or Investor Relations, Lilian Stern of Stern Investor Relations, Inc., +1-212-362-1200, or , for AtheroGenics, Inc. Web site: http://www.atherogenics.com/

Copyright